Atlas Trials

Registry on the Effectiveness and Safety of the 9-month MDR-END Treatment Regimen in Korean Patients with FQ-sensitive MDR-TB (MDR-END Registry)

Clinical trial NCT06674291 · NOT_YET_RECRUITING

Trial details

NCT number
NCT06674291
Sponsor
Korea Otsuka Pharmaceutical Co., Ltd.
Status
NOT_YET_RECRUITING
Study type
OBSERVATIONAL
Tuberculosis, Multidrug-Resistant
Start date
2024-11-30
Primary completion
2027-12-31
Enrollment
222

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.